Technical Analysis for BDSX - Biodesix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.58 | 0.96% | 0.02 |
BDSX closed up 0.96 percent on Friday, May 17, 2024, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 200 DMA | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
NR7 | Range Contraction | 0.96% | |
NR7-2 | Range Contraction | 0.96% |
Alert | Time |
---|---|
Possible NR7 | 1 day ago |
60 Minute Opening Range Breakout | 1 day ago |
Up 1% | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
200 DMA Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2024
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.21 |
52 Week Low | 1.03 |
Average Volume | 149,181 |
200-Day Moving Average | 1.56 |
50-Day Moving Average | 1.39 |
20-Day Moving Average | 1.41 |
10-Day Moving Average | 1.54 |
Average True Range | 0.08 |
RSI (14) | 66.10 |
ADX | 22.85 |
+DI | 26.10 |
-DI | 15.53 |
Chandelier Exit (Long, 3 ATRs) | 1.38 |
Chandelier Exit (Short, 3 ATRs) | 1.45 |
Upper Bollinger Bands | 1.69 |
Lower Bollinger Band | 1.13 |
Percent B (%b) | 0.8 |
BandWidth | 39.65 |
MACD Line | 0.06 |
MACD Signal Line | 0.04 |
MACD Histogram | 0.0214 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.61 | ||||
Resistance 3 (R3) | 1.60 | 1.59 | 1.60 | ||
Resistance 2 (R2) | 1.59 | 1.58 | 1.59 | 1.60 | |
Resistance 1 (R1) | 1.58 | 1.58 | 1.59 | 1.59 | 1.60 |
Pivot Point | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
Support 1 (S1) | 1.56 | 1.56 | 1.57 | 1.57 | 1.55 |
Support 2 (S2) | 1.55 | 1.56 | 1.55 | 1.55 | |
Support 3 (S3) | 1.54 | 1.55 | 1.55 | ||
Support 4 (S4) | 1.55 |